小分子抑制によるTNF-αの抑制
Molly M He1, Annemarie Stroustrup Smith, Johan D Oslob
1Sunesis Pharmaceuticals, Incorporated, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA.
まとめ
新しい小分子阻害剤は,そのサブユニット解離を促進することによって,腫瘍死滅因子α (TNF-α) を破壊する. この化合物は,TNF-αの活性を効果的に抑制し,新しい治療法を提供しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- 構造生物学 構造生物学とは
背景:
- 腫瘍死滅因子アルファ (TNF-alpha) は,様々な疾患に関与する重要な炎症性サイトカインです.
- TNF-αはトリメアタンパク質として機能し,その活動はこの四分構造に依存しています.
研究 の 目的:
- TNF-αトリマーを標的とする小分子阻害剤を特定し,特徴づけること.
- 抑制剤がTNF-αの構造と機能を破壊するメカニズムを解明する.
主な方法:
- 生化学的および細胞ベースの測定は,TNF-α抑制活性を評価するために使用されました.
- X線結晶学を用いて,阻害の構造的基礎を決定した.
主要な成果:
- TNF-αを阻害する新しい小分子が生物化学的および細胞ベースの測定では,それぞれ22および4.6マイクロモルの中位抑制濃度で特定されました.
- この化合物は,TNF-αサブユニット解離を600倍加速し,トリマーの解離につながります.
- X線結晶学では,阻害剤がTNF-αサブユニットのダイマーに結合し,1つのサブユニットを置換することを明らかにした.
結論:
- この研究は,TNF-αトリマーを効果的に分解する小分子阻害剤を提示しています.
- このメカニズムは,TNF-αサブユニットと直接相互作用し,機能的抑制につながります.
- この阻害剤は,TNF-α媒介性疾患に対する有望な治療戦略を表しています.
さらに関連する動画
07:49Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
関連する概念動画
NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
